Cumulus Oncology, Europe’s first oncology-focused biotech creation company, announces that, in partnership with its collaborator leadXpro (LXP), key milestones have been achieved in their protein structure driven GPR68 drug discovery project. As a result, Cumulus has licensed the small molecule compounds and associated IP created during this collaboration and will continue the programme to lead optimisation and beyond.
In July 2023, Cumulus Oncology and LXP announced a collaboration to develop small molecules against GPR68, an important proton sensing G protein coupled receptor (GPCR), using the latest cutting-edge computational, biophysical and structural biology technologies. Achieving a world first, LXP has solved high-resolution antagonist protein structures of GPR68, rapidly informing compound design. This has enabled the partnership to identify, in under 12 months, a series of potent and selective small molecules for therapeutic intervention in cancer and inflammation, leading to this licensing event. The collaboration will now move to an accelerated drug optimisation phase leveraging these established cutting-edge rational drug design and computational techniques.
Also Read: Agilisium Recognized as a Leader in Everest Group Life Sciences Digital Services for Mid-Market Enterprises PEAK Matrix®Report
LXP will receive a share in revenues from future commercialisation of the project. Further financial details are not disclosed. As the GPR68 programme progresses, Cumulus plans to file for regulatory approval to start clinical development through its Swiss-based portfolio company, GIO Therapeutics, which has been incorporated to develop a portfolio of GPCR targeting assets. The GPR68 programme represents the first programme that will be developed by GIO Therapeutics.
Cumulus Oncology’s CEO Clare Wareingsaid, “The LeadXpro team are world leading experts in GPCR drug discovery and deciphering membrane protein structures to improve human health. This successful collaboration, and the milestones achieved, have resulted in the licensing agreement between Cumulus and LXP, exemplifying the Cumulus model. Cumulus takes a platform and modality agnostic approach to identifying new targets and assets, seeking out opportunities that have the potential to transform therapeutic options for patients poorly served by existing treatments. When these assets reach key inflection points, they are taken forward in new companies that we create and manage.”
leadXpro’s Co-founder, CEO, and Chairman of the Board, Michael Hennig added, “We’re delighted to have achieved this major drug development milestone working with Cumulus Oncology. Clare and her team share our passion for structure-based drug discovery. Together we have achieved fantastic success with our medicinal, computational chemistry, biophysics and structural biology input in a short span of time. We are looking forward to continuing the collaboration on this therapeutically important proton sensing GPCR. This continues to be a very positive relationship and shows us to be the partner of choice for structure-based drug design of novel membrane protein targets.”
Source: GlobeNewsWire
